Form 4: BridgeBio Pharma CFO Thomas Trimarchi Receives Stock Grant and Executes Power of Attorney

BridgeBio Pharma's CFO, Thomas Trimarchi, received a grant of restricted stock units and also executed a limited power of attorney for SEC filings.

Summary

• Thomas Trimarchi, CFO of BridgeBio Pharma, received 109,100 restricted stock units (RSUs) on March 19, 2025.
• These RSUs will vest in equal quarterly installments over four years, starting May 16, 2025, contingent upon continued service with the company.
• Each RSU represents the right to receive one share of BridgeBio Pharma's common stock.
• Following the transaction, Trimarchi beneficially owns 523,305 shares of common stock.
• Trimarchi also executed a limited power of attorney on July 23, 2024, granting certain individuals the authority to handle SEC filings on his behalf.

Sentiment

Score: 7

Explanation: The sentiment is neutral to positive. The RSU grant is a standard practice and aligns the CFO's interests with shareholders. The power of attorney is an administrative matter.

Positives

• The grant of RSUs to the CFO aligns his interests with those of the shareholders, incentivizing him to contribute to the company's long-term success.

Future Outlook

The RSUs will continue to vest quarterly until fully vested, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date.

Industry Context

Stock grants are a common practice in the pharmaceutical industry to incentivize and retain key executives. The vesting schedule encourages long-term commitment to the company's goals.

Comparison to Industry Standards

• Stock grants to CFOs in the biotech industry typically range from \$500,000 to \$2 million annually, depending on the company's size and performance.
• Vesting schedules are generally structured over a three-to-four-year period to align executive compensation with long-term shareholder value.
• Comparable companies like Amgen, Gilead, and Biogen also utilize stock grants as part of their executive compensation packages.

Stakeholder Impact

• Shareholders may view the RSU grant positively as it incentivizes the CFO to work towards increasing shareholder value.
• The CFO is incentivized to remain with the company to realize the full value of the RSUs.

Key Dates

Keywords

BridgeBio Pharma, Thomas Trimarchi, CFO, Restricted Stock Units, RSUs, Beneficial Ownership, Power of Attorney, SEC Filings, Vesting